Yahsou Delmas

List of Publications by Year
in descending order

16 papers	1,353 citations	687363 13 h-index	940533 16 g-index
16 all docs	16 docs citations	16 times ranked	1255 citing authors

#	Article	IF	Citations
1	Urine Protein/Creatinine Ratio in Thrombotic Microangiopathies: A Simple Test to Facilitate Thrombotic Thrombocytopenic Purpura and Hemolytic and Uremic Syndrome Diagnosis. Journal of Clinical Medicine, 2022, 11, 648.	2.4	3
2	Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes. Journal of Clinical Medicine, 2022, 11, 790.	2.4	1
3	A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood, 2021, 137, 733-742.	1.4	95
4	Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood, 2021, 137, 2438-2449.	1.4	87
5	Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrology Dialysis Transplantation, 2020, 35, 2147-2153.	0.7	15
6	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood, 2020, 136, 2103-2117.	1.4	82
7	The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naÃ¯ve to complement inhibitor treatment. Kidney International, 2020, 97, 1287-1296.	5.2	123
8	Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival. Blood, 2019, 134, 2209-2217.	1.4	38
9	Atypical and secondary hemolytic uremic syndromes have a distinct presentation andÂnoÂcommon genetic risk factors. Kidney International, 2019, 95, 1443-1452.	5.2	74
10	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2019, 30, 2449-2463.	6.1	81
11	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1237-1247.	4.5	146
12	Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 50-59.	4.5	148
13	Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrology Dialysis Transplantation, 2016, 31, 2122-2130.	0.7	72
14	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney International, 2015, 87, 1061-1073.	5.2	342
15	Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. CKJ: Clinical Kidney Journal, 2013, 6, 243-244.	2.9	30
16	Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: A pediatric report and literature review. Pediatric Critical Care Medicine, 2011, 12, e90-e93.	0.5	16